诱导化疗联合同步放化疗治疗进展期食管癌的疗效评价(1)
[摘要] 目的 分析進展期食管癌患者接受诱导化疗联合同步放化疗的临床应用价值。方法 该次方便选择2017年1月—2019年1月该院收治进展期食管癌患者79例为研究对象，参照计算机抽选结果分为观察组与对照组，对照组患者单纯接受放疗治疗，观察组患者接受诱导化疗联合同步放化疗治疗，比较近期疗效，统计并分析各组患者治疗前后免疫功能指标变化，记录并计算不良反应发生概率。结果 观察组患者近期总疗效明显高于对照组(χ2=5.93，P<0.05)，两组患者未接受放化疗治疗前免疫功能各项指标差异无统计学意义(P>0.05)，经治疗后，对照组患者CD3+指标(62.59±1.03)、CD4+指标(33.81±0.38)、CD8+指标(31.35±0.03)、CD3+/CD8+指标(0.95±0.02)均优于观察组(t=8.51、9.92、7.82、7.36，P<0.05)。同时，对照组患者出现不良反应的概率较观察组相比更低。结论 进展期食管癌患者接受诱导化疗联合同步放化疗治疗近期效果更佳，但对患者免疫功能造成的损害相对较大，不良反应较高，临床应结合患者对放化疗的耐受性合理选择针对性治疗措施。
, 百拇医药
[关键词] 诱导化疗;同步放化疗;进展期食管癌;疗效;免疫功能
[中图分类号] R735 [文献标识码] A [文章编号] 1674-0742(2019)10(c)-0017-03
[Abstract] Objective To analyze the clinical value of induction chemotherapy combined with concurrent chemoradiotherapy in patients with advanced esophageal cancer. Methods From January 2017 to January 2019， 79 patients with advanced esophageal cancer were convenient selected and enrolled in the hospital. The results were divided into observation group and control group by computer sampling. The control group received radiotherapy alone. Observation group of the patients received induction chemotherapy combined with concurrent chemoradiotherapy. The short-term effects were compared. The changes of immune function indexes before and after treatment were statistically analyzed. The probability of adverse reactions was recorded and calculated. Results The total effect of the patients in the observation group was significantly higher than that of the control group (χ2=5.93， P<0.05). There was no significant difference in the immune function between the two groups before receiving chemoradiotherapy(P>0.05). After treatment， the CD3+ index of the control group (62.59±1.03)， CD4+ index (33.81±0.38)， CD8+ index (31.35±0.03)， CD3+/CD8+ index (0.95±0.02) were better than observation group (t=8.51， 9.92， 7.82， 7.36，P<0.05). At the same time， the probability of adverse reactions in the control group was lower than that in the observation group. Conclusion The patients with advanced esophageal cancer receiving induction chemotherapy combined with concurrent chemoradiotherapy have better short-term effects， but the damage caused by immune function is relatively large， and the adverse reactions are high. The clinical combination should be based on the patient's tolerance to radiotherapy and chemotherapy treatment measures., 百拇医药(靳晓伟 陈雷 顾丽英 周雷)
, 百拇医药
[关键词] 诱导化疗;同步放化疗;进展期食管癌;疗效;免疫功能
[中图分类号] R735 [文献标识码] A [文章编号] 1674-0742(2019)10(c)-0017-03
[Abstract] Objective To analyze the clinical value of induction chemotherapy combined with concurrent chemoradiotherapy in patients with advanced esophageal cancer. Methods From January 2017 to January 2019， 79 patients with advanced esophageal cancer were convenient selected and enrolled in the hospital. The results were divided into observation group and control group by computer sampling. The control group received radiotherapy alone. Observation group of the patients received induction chemotherapy combined with concurrent chemoradiotherapy. The short-term effects were compared. The changes of immune function indexes before and after treatment were statistically analyzed. The probability of adverse reactions was recorded and calculated. Results The total effect of the patients in the observation group was significantly higher than that of the control group (χ2=5.93， P<0.05). There was no significant difference in the immune function between the two groups before receiving chemoradiotherapy(P>0.05). After treatment， the CD3+ index of the control group (62.59±1.03)， CD4+ index (33.81±0.38)， CD8+ index (31.35±0.03)， CD3+/CD8+ index (0.95±0.02) were better than observation group (t=8.51， 9.92， 7.82， 7.36，P<0.05). At the same time， the probability of adverse reactions in the control group was lower than that in the observation group. Conclusion The patients with advanced esophageal cancer receiving induction chemotherapy combined with concurrent chemoradiotherapy have better short-term effects， but the damage caused by immune function is relatively large， and the adverse reactions are high. The clinical combination should be based on the patient's tolerance to radiotherapy and chemotherapy treatment measures., 百拇医药(靳晓伟 陈雷 顾丽英 周雷)